Log In Get Started
Insider Trading April 17, 2026 06:28 PM

MapLight CFO Sells $78,572 in Stock as Shares Climb Toward 52-Week High

Setia Vishwas disposes of 2,922 shares over two days; analysts highlight upcoming Phase II readout for lead schizophrenia candidate

By Marcus Reed MPLT
MapLight CFO Sells $78,572 in Stock as Shares Climb Toward 52-Week High
MPLT

MapLight Therapeutics Chief Financial Officer Setia Vishwas sold 2,922 shares of the company’s voting common stock on April 15 and 16, 2026, in transactions that totaled $78,572. The sales, executed at prices between $26.87 and $27.49, were disclosed in a Form 4 filing with the SEC and were reported to satisfy statutory tax withholding tied to restricted stock unit vesting. The stock has since traded higher, nearing its 52-week peak, while analysts continue to flag upcoming Phase II data for the company’s lead asset.

Key Points

  • CFO Setia Vishwas sold 2,922 shares on April 15-16, 2026, for a total of $78,572 at prices between $26.87 and $27.49.
  • The sales were reported to cover statutory tax withholding obligations tied to restricted stock units; afterwards Vishwas directly owns 392,627 shares.
  • MapLight shares have risen to $30.05, trading near a 52-week high of $31.13 and up 71% year-to-date; analysts from TD Cowen and Stifel have active coverage noting an upcoming Phase II readout for ML-007C-MA.

Setia Vishwas, the Chief Financial Officer of MapLight Therapeutics, Inc. (NASDAQ:MPLT), reported the sale of 2,922 shares of Voting Common Stock in transactions conducted on April 15 and April 16, 2026, according to a Form 4 filing submitted to the Securities and Exchange Commission.

The filings show the total proceeds from the trades were $78,572, with execution prices spanning from $26.87 to $27.49. The breakdown of the reported transactions is as follows:

  • April 15, 2026 - 2,806 shares sold at $26.87;
  • April 16, 2026 - 29 shares sold at $27.01;
  • April 16, 2026 - 87 shares sold at $27.49.

Following these dispositions, the filing indicates that Setia Vishwas directly holds 392,627 shares of MapLight Therapeutics. The reported sales were carried out to meet statutory tax withholding obligations associated with the vesting of restricted stock units.

Market activity since the disclosed sales shows the stock rising to $30.05, trading close to a 52-week high of $31.13, and the shares have climbed 71% year-to-date.

Separately, analysis from InvestingPro cited in the filing notes that MapLight’s shares currently appear overvalued relative to the service’s Fair Value assessment, and that InvestingPro provides 12 additional exclusive tips for MPLT covering the company’s financial health and momentum indicators.

Analyst coverage of MapLight has also been active. TD Cowen initiated coverage with a buy rating, calling attention to MapLight’s pipeline of treatments intended for central nervous system and neuropsychiatric disorders and specifically highlighting the lead asset, ML-007C-MA, which is designed to improve the treatment profile for schizophrenia. The firm noted Phase II data for that candidate is anticipated in the third quarter of this year.

Stifel reiterated its buy rating and kept a $28.00 price target following MapLight’s fourth-quarter update. In its commentary, Stifel pointed out that phase 2 data for ML-007C-MA remain on schedule for a topline readout in the third quarter of 2026 and expressed interest in potential differentiation on tolerability, safety, or dosing frequency.

These disclosed insider sales, the stock’s recent price performance, and the analyst attention on the company’s lead candidate together reflect ongoing market and investor focus on MapLight Therapeutics and its clinical timelines.

Risks

  • Timing risk around clinical data - Phase II data for ML-007C-MA are anticipated in the third quarter of this year and for Stifel the topline readout is on schedule for the third quarter of 2026, creating reliance on clinical milestones.
  • Valuation uncertainty - InvestingPro analysis indicates the stock appears overvalued relative to its Fair Value, introducing market risk for investors.
  • Insider selling for tax purposes may be viewed variably by markets - while the filing states the sales covered statutory tax withholding from RSU vesting, such transactions can still create short-term market noise in the healthcare and biotech sectors.

More from Insider Trading

Magnetar Affiliates Dispose $309M of CoreWeave Class A Stock Amid Major Corporate Developments Apr 17, 2026 Magnetar-Linked Funds Sell $50.1M of CoreWeave Stock; Strategic Deals and Financing Continue to Shape Outlook Apr 17, 2026 System1 CFO Makes $80,730 Stock Purchase Amid Deepening Share Decline Apr 17, 2026 Aehr Test Systems Director Sells $2.125M in Stock as Company Logs Record Order and Mixed Quarterly Results Apr 17, 2026 Clene Inc. 10% Holder Ugwumba Chidozie Sells $251,897 in Stock Over Three Days Apr 17, 2026